Aviado · Research
Longevity Daily
Tuesday, November 3, 2026
Listen
Today's Brief
Blood may soon be the window into future brain health: a landmark study of 12,000 women reveals that 16 aging-linked proteins surge during the menopause transition—the clearest early signal for dementia risk ever captured at this scale. Meanwhile, The New Yorker asks a hard question: now that blood tests can flag cognitively normal people for Alzheimer's amyloid, what do we do when no proven prevention yet exists? In supplements, Aviado unpacks niacin's underappreciated dual mechanism for cutting triglycerides and fighting inflammation simultaneously, and a provocative new cell study finds that metformin broadly outperformed rapamycin at slowing molecular aging.
10 stories2 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
A Panel of 16 Blood Proteins Predicts Dementia Risk During the Menopause Transition
A study of 12,000 women found that 16 blood proteins linked to brain aging spike sharply during the menopause transition, creating a distinct biological window that could one day screen women for elevated dementia risk years before symptoms appear. The proteins include markers tied to neuroinflammation and vascular function—two pathways central to Alzheimer's risk in women. Crucially, the changes occur during perimenopause, when interventions such as hormone therapy, lifestyle modification, or targeted supplementation may still have meaningful impact. If validated clinically, this panel could reshape the standard of care for women's brain health in midlife.
Read more →Millions of People Now Test Positive for Alzheimer's Amyloid—But No Proven Treatment Exists for Them
New blood tests can detect amyloid in cognitively normal people, but no treatment has been shown to prevent decline in this asymptomatic population—and the two newly FDA-approved antibodies were tested only in patients with early symptoms. The New Yorker's investigation raises hard questions about mass screening, the psychological burden of a diagnosis that may never cause disease, and the risk of medicating tens of millions on a biomarker rather than clinical decline. Until ongoing trials answer whether treating pre-symptomatic amyloid actually prevents cognitive loss, experts urge significant caution about routine testing outside research settings.
Read more →Purdue Researchers Find a New Pathway to Alzheimer's Resilience—and It's in the Mitochondria
A National Institute on Aging-funded team at Purdue identified a novel mechanism underlying cognitive resilience in Alzheimer's disease, with findings pointing to mitochondrial function rather than amyloid clearance. Unlike the monoclonal antibodies currently approved—which target plaques and carry risks of brain inflammation—this approach focuses on a parallel biological pathway that could sidestep those side effects entirely. If confirmed in human trials, this mechanism could seed a new class of Alzheimer's interventions that complement the existing treatment landscape.
Read more →Supplements & Compounds
One Receptor, Two Benefits: How Niacin Simultaneously Cuts Triglycerides and Fights Inflammation
Niacin works differently from most supplements because it activates a single receptor—GPR109A on fat cells and immune cells—that simultaneously suppresses fatty acid release into the bloodstream and boosts adiponectin, a hormone that combats inflammation and improves insulin sensitivity. Clinical trials show extended-release niacin at 1,000–2,000 mg daily produces 20–30% reductions in triglycerides, with adiponectin levels sometimes more than doubling. Aviado's analysis explains why this dual mechanism delivers metabolic benefits that go well beyond what cholesterol panels alone would predict, and how to dose gradually to minimize the flushing that makes immediate-release forms hard to tolerate.
Read the full Aviado analysis →Green Tea Compound EGCG Linked to Slower Biological Aging in 11,000-Person Study
Analyzing data from 10,977 NHANES participants, researchers found that people who consumed EGCG—the major polyphenol in green tea—had meaningfully lower biological age acceleration and reduced all-cause mortality compared to non-consumers. Follow-up experiments in C. elegans and liver cells revealed the mechanism: EGCG activates peroxisome biogenesis, enhancing the cellular machinery that processes long-chain fatty acids and clears age-accelerating waste. Published in Aging Cell, this is one of the stronger human-scale studies connecting a widely available food compound to biological aging markers, though optimal dosing and frequency in humans still need to be established.
Read more →Research & Papers
A Safer Reprogramming Approach Delivers Cellular Rejuvenation Without the Risk of Going Too Far
One of the biggest safety concerns in Yamanaka factor reprogramming—where cells can rejuvenate epigenetically but risk losing their identity and turning cancerous—may have a new solution: delivering the four factors via circular RNA, which drives rejuvenation while preventing the runaway dedifferentiation that makes tissue-level reprogramming dangerous. Researchers demonstrated that this delivery format produced epigenetic rejuvenation without full stem-cell conversion in a tissue environment. The approach is still early-stage, but closing this safety gap is considered one of the key hurdles blocking clinically viable reprogramming therapies.
Read more →In a New Human Cell Aging Platform, Metformin Broadly Outperformed Rapamycin
Using a novel system that accelerates aging features in human fibroblasts, researchers tested two of the most-discussed longevity compounds head to head: metformin broadly attenuated both transcriptomic and epigenetic aging markers, while rapamycin showed limited efficacy in the same model. The platform also converts aged fibroblasts into neurons, enabling pseudo-longitudinal modeling of neuronal aging that could accelerate future drug screening. Published in Aging Cell, this is a cell culture study—not a human RCT—so results are preliminary, but for the rapamycin-following community, it is data worth watching closely.
Read more →Lifestyle & Nutrition
Older Adults Who Voted in Two Presidential Elections Were Far Less Likely to Die Early
A first-of-its-kind study found that older Americans who voted in two consecutive presidential elections had substantially lower rates of premature death than non-voters—adding civic participation to a growing list of social behaviors linked to longevity. Researchers suspect the association reflects a cluster of factors: stronger social ties, greater sense of purpose, and the health-promoting behaviors that voting tends to signal. The study cannot prove that voting causes longer life, but it adds to consistent evidence that social agency and participation are powerful—and underrated—drivers of healthspan.
Read more →Industry & Policy
Immorta Bio Administers the World's First Senolytic Immunotherapy to a Human Patient
Immorta Bio announced the first-ever human administration of a senolytic immunotherapy—a biological treatment designed to selectively eliminate the senescent zombie cells that accumulate with age and fuel chronic inflammation across multiple organ systems. The trial is deliberately starting in advanced cancer patients to establish safety before expanding into broader diseases of aging. This milestone puts immunotherapy-based senolysis—long discussed as a theoretical frontier for aging medicine—into active human clinical testing for the first time.
Read more →A New Federal Peptide Compounding Policy Reshapes the Landscape for Supplement Brands
HHS has released an interim policy creating a compounding pathway for certain peptides, significantly changing the regulatory backdrop for supplement brands competing against gray-market peptide products. While technically a drug-compounding framework rather than a supplement approval, the policy alters drug-preclusion arguments that have historically been used to block supplement versions of the same compounds. Industry counsel describe this as one of the most consequential regulatory shifts since DSHEA passed in 1994—and brands selling any peptide-adjacent products should understand how it changes their exposure.
Read more →